Study of Monoclonal Antibodies in Cancer Resistance
Author Information
Author(s): I. Sugawara, H. Kodo, E. Ohkochi, H. Hamada, T. Tsuruo, S. Mori
Primary Institution: Institute of Medical Science, University of Tokyo
Hypothesis
Can MRK 16 and MRK 20 monoclonal antibodies help detect multidrug-resistant cancer cells in leukemia and lymphoma?
Conclusion
The study found that MRK 20-positive cells were frequently present in leukemia and lymphoma, indicating a potential marker for multidrug resistance.
Supporting Evidence
- MRK 16 reactivity was observed in five cases, while MRK 20 reactivity was seen in 18 cases.
- An increase in MRK 16-positive cells was linked to prior administration of anticancer drugs.
- MRK 20-positive cells were detected both before and during treatment, indicating intrinsic drug resistance.
Takeaway
This study looked at how certain proteins in cancer cells can show if they are resistant to treatment, helping doctors know how to fight the cancer better.
Methodology
Flow cytometry and immunocytochemistry were used to analyze the reactivity of monoclonal antibodies with patient samples.
Limitations
The study could not determine the exact timing of P-glycoprotein appearance during treatment.
Participant Demographics
Patients with leukemia or malignant lymphoma, referred for evaluation and therapy.
Want to read the original?
Access the complete publication on the publisher's website